Topics:
Pediatric Oncology • ALL
Would you change TKIs in a patient with Ph-Like or Ph-positive B cell ALL who relapses on therapy (along with giving relapse chemotherapy)?
For example, if the patient was on dasatinib before relapse, would you consider other second generation or third generation TKIs?
Answer from: at Community Practice
Mechanisms of resistance in Ph-like ALL have not been extensively studied and will definitively be an active area of research. Given the biological similarities between Ph+ ALL and Ph-like ALL, one could hypothesize that similar mechanisms of resistance could occur in both entities. Kinase domain (K...
Sign in or Register to read more